Panacea Life Sciences Holdings, Inc.
Panacea Life Sciences Holdings, Inc.
Your view on PLSH
Overview
What the company does, where it operates, and who runs it.
About Panacea Life Sciences Holdings, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Leslie A. Buttorff
- Headquarters
- 5910 South University Boulevard, Greenwood Village, CO, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Leslie A. Buttorff
- Headquarters
- 5910 South University Boulevard, Greenwood Village, CO, US
Panacea Life Sciences Holdings, Inc., a seed to sale cannabinoid and nutraceutical manufacturer and research company, develops and produces natural pharmaceutical alternatives for consumers and pets. The company manufactures and sells softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.
It is also involved in the personal protection equipment (PPE) business, including importing and selling PPE hand sanitizers and masks, as well as white label and contract manufacturing sales to other cannabinoid companies, raw material sales, and tolling arrangements.
The company was incorporated in 2008 and is headquartered in Greenwood Village, Colorado.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Panacea Life Sciences Holdings, Inc., and the rating behind it. PLSH last traded at $0.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Panacea Life Sciences Holdings, Inc.. Starting points for Panacea Life Sciences Holdings, Inc.: EPS -$0.10, beta 3.31 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Panacea Life Sciences Holdings, Inc.. Panacea Life Sciences Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Panacea Life Sciences Holdings, Inc.. Trailing twelve-month EPS for Panacea Life Sciences Holdings, Inc. stands at -$0.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Panacea Life Sciences Holdings, Inc.. Panacea Life Sciences Holdings, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Panacea Life Sciences Holdings, Inc. valued side by side against its closest peers. Panacea Life Sciences Holdings, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Panacea Life Sciences Holdings, Inc., and how their positions are changing. At a $870,175 market value, institutional positions materially move Panacea Life Sciences Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Panacea Life Sciences Holdings, Inc. executives and directors. Shares of Panacea Life Sciences Holdings, Inc. have traded between $0.03 and $0.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Panacea Life Sciences Holdings, Inc.. Panacea Life Sciences Holdings, Inc. is a $870,175 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Panacea Life Sciences Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Panacea Life Sciences Holdings, Inc.. Coverage tracks Panacea Life Sciences Holdings, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.